therapeutic implications, with pAF being more amenable to rhythm control therapy. 6 Current pharmacological options have imperfect efficacy and substantial adverse side effects, including drug-induced proarrhythmia and both cardiac and noncardiac toxicity. [7] [8] [9] The limited efficacy of current pharmacological treatment options likely results from an incomplete understanding of the pathophysiology of this complex heart rhythm disorder. Here, we provide a conceptual overview of the factors involved in the initiation, maintenance, and progression of AF. Subsequently, we review the molecular mechanisms identified for each of these components. Finally, we highlight important gaps in the current understanding of AF pathophysiology, particularly with respect to the translation of these findings to the clinical setting.
Conceptual Framework AF as a Progressive Disease
The pathophysiology of AF contains 3 major components: initiation of the arrhythmia, arrhythmia maintenance, and progression toward longer-lasting AF forms (ie, from paroxysmal to persistent/permanent AF). 10, 11 Each AF episode requires initiation by a trigger acting on a vulnerable substrate. This vulnerable substrate is at least partly determined by genetic factors. [12] [13] [14] Several mutations and gene variants have been identified that allow AF initiation in the absence of traditional risk factors ( Figure 1A ). Although they are rare, and generally limited to isolated families, AF-causing mutations have provided important insights into the ionic mechanisms underlying AF. 12 In addition, recent genome-wide association studies have discovered several genetic variants associated with an increased risk of AF, identifying novel potential factors contributing to AF. 13 However, the exact mechanisms linking genetic loci identified with genome-wide association studies to AF are incompletely understood, because (1) causative genes are often uncertain, and (2) the likely candidates generally have poorly understood functions. Even after including genome-wide association study variants, a large portion of the heritability of AF is uncertain, with large population studies showing that a parental history of AF almost doubles the future AF risk in their offsprings. 14 Thus, other currently unknown genetic components also play a role in more common forms of AF. 13 Furthermore, genetic variants are unlikely to cause AF directly, but rather provide background vulnerability. When additional risk factors develop over time, because of physiological aging or cardiac remodeling resulting from other cardiovascular and noncardiovascular diseases, an appropriate trigger may then initiate AF ( Figure 1B ). Common comorbidities that promote a vulnerable substrate for the initiation and maintenance of AF include hypertension, HF, and cardiac valve disease. 5 Genetic variants that increase the risk of hypertension, valve disease, and other AF risk factors may, therefore, also augment the risk of AF, even when not directly affecting the atria. A detailed discussion of the relationships among clinical features, epidemiology, and arrhythmogenic mechanisms is provided in another article in this compendium, along with an overview of AF pathophysiology. 15 About 5% of patients with pAF progress to persistent forms each year. 11 Further progression occurs at increasing rates, with 35% to 40% of patients with persistent AF developing permanent AF <1 year. 4 The progression rate is lowest in young patients without associated heart disease (lone AF), amounting to 1% to 3% per year. 16 However, there exists a wide variability in AF progression among patients. In some cases, AF initially presents as persistent AF ( Figure 1C) . 11 When AF is maintained, it causes atrial tachycardia-induced remodeling, increasing substrate vulnerability and promoting AF maintenance, progression, and stabilization. It must be recognized that Figure 1 is a schematic presentation of our present concepts of common forms of AF evolution, and that other clinical forms are possible, for example, recurrent paroxysmal AF that never becomes persistent, and initial presentation with persistent AF that is never terminated, whether because treating physicians decide that AF conversion is unnecessary or because successful conversion to sinus rhythm proves impossible.
Fundamental AF Mechanisms
Ectopic (triggered) activity and re-entry are major arrhythmogenic mechanisms in AF (Figure 2) . 10, 17, 18 Focal ectopic/triggered activity is likely caused by early afterdepolarizations (EADs) and delayed afterdepolarizations (DADs). EADs are favored by delayed repolarization, whereas DADs depend on Ca 2+ -handling abnormalities. an anatomic obstacle when each point in the pathway has sufficient time to regain excitability before the arrival of the next impulse. The likelihood of anatomic re-entry is controlled by the wavelength (conduction velocity × effective refractory period). 7 Re-entry can also be functional, when premature impulses conduct unidirectionally around an initially refractory border. Several conceptual interpretations of functional reentry exist. 17, 18 In the leading circle model, re-entry occurs in a circuit with a size equal to the wavelength with a central continuously refractory core, whereas in the spiral wave model, B C A Figure 1 . Conceptual framework of atrial fibrillation (AF) initiation, maintenance, and progression. A, In patients with a sufficiently large genetic predisposition, AF onset may occur at a relatively young age. AF-induced remodeling helps to maintain the arrhythmia, as well as promoting AF progression. B, In most patients, the genetic substrate alone does not provide sufficient susceptibility for AF. Additional disease-related remodeling may increase vulnerability and allow the initiation of paroxysmal AF episodes. Over time, some patients with paroxysmal AF may progress to longer-lasting persistent AF forms. C, Because of the composition of substrate and trigger, some patients have a first AF episode lasting >7 d and may progress to permanent AF due either to progression of underlying disease or to a medical decision to leave the patient in AF. (Note that for convenience the time scale for AF episodes, in gray, is expanded compared with the lower axis providing a sense of lifetime time course.) excitation proceeds around a central core of excitable but unexcited tissue (Figure 2) . 17 Focal ectopic firing can also arise from microre-entrant circuits that, at the macroscopic level, cannot be distinguished from EAD-/DAD-mediated triggered activity.
Focal ectopic firing is required for the initiation of AF in a vulnerable substrate. In addition, it can maintain AF when occurring repetitively at a high frequency. Multiple circuit reentry or one or more rotors with fibrillatory conduction are the most likely mechanisms for the maintenance of long-standing AF episodes in the majority of patients.
Mechanisms of AF Initiation Atrial Cellular Electrophysiology and Ectopic/ Triggered Activity
During normal sinus rhythm, atrial action potentials (APs) are initiated through voltage-dependent activation of cardiac Na + channels, producing a depolarizing current (I Na ) responsible for the AP upstroke. . APD prolongation allows time for L-type Ca 2+ channels to recover from inactivation, resulting in an inward current, causing an EAD ( Figure 3A ). DADs predominantly arise from abnormal SR Ca 2+ leak and diastolic SR Ca 2+ release events (SCaEs) and are promoted by increased SR Ca 2+ load and RyR2 dysfunction ( Figure 3B ). Diastolic Ca 2+ release from the SR activates NCX, producing a transient-inward current that causes membrane depolarization ( Figure 3B ). If the DAD reaches threshold, a triggered ectopic AP results.
Role of Ectopic/Triggered Activity for AF Initiation

Ca
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-Handling Abnormalities Promote DAD-Related Ectopic Activity Much less is known about the conditions causing clinically relevant ectopic activity than those permitting re-entry. Several mouse models have highlighted an important role for RyR2 dysfunction, increased SR Ca 2+ leak, and SCaEs in initiating AF. Mice lacking the RyR2-stabilizing subunit FKBP12.6 show larger SR Ca 2+ leak and more SCaEs, leading to NCX activation and DADs. 22 They also show increased susceptibility to burst pacing-induced AF, but without spontaneous AF episodes in vivo. 22 Similar results are obtained in mice with the E169K mutation in junctophilin-2, which shows reduced interaction with RyR2, suggesting an important RyR2-stabilizing role for junctophilin-2. 23 Gain-of-function mutations in RyR2 predispose patients to catecholaminergic polymorphic ventricular tachycardia and AF, 24, 25 -handling abnormalities also contribute to AF initiation in large animal models. For example, chronic atrial ischemia/infarction creates a substrate for focal ectopic activity characterized by SCaEs and increased NCX current, particularly in the setting of β-adrenoceptor stimulation. 29 Indeed, sympathetic stimulation provides an important trigger promoting Ca 2+ -handling abnormalities and AF initiation. 30 Some transgenic mouse lines develop spontaneous AF episodes, 31 with the majority of these showing pronounced structural remodeling with atrial dilatation and fibrosis, 31 but the exact molecular mechanisms underlying the initiation of AF episodes remain largely unknown.
Mice with cardiac-restricted overexpression of a repressor form of the cAMP-response element modulator (CREM) develop a complex cardiac phenotype including spontaneousonset AF. 32 -handling abnormalities in spontaneous AF, because CREM-transgenic mice treated with the SERCA2a inhibitor thapsigargin showed a reduced incidence of spontaneous AF. 32 CaMKII-dependent hyperphosphorylation of RyR2 is likely an early event in the atrial pathogenesis of CREM-transgenic mice, because when CREM-transgenic mice are crossed with RyR2-S2814A-transgenic mice resistant to CaMKII-dependent RyR2 hyperphosphorylation, spontaneous AF is eliminated. 33 Transforming growth factor β1 (TGFβ1) plays a critical role in the development of atrial fibrosis by promoting fibroblast proliferation and differentiation into collagen-secreting myofibroblasts. 34 Mice overexpressing constitutively active TGFβ1 develop extensive atrial fibrosis. 35 Although they do not show spontaneous AF, they have inducible AF on burst pacing. 35, 36 Optical mapping suggests an important role for Ca 2+ transient-triggered depolarizations during late phase 3 of the AP in AF initiation. 36 Consistent with a Ca 2+ -dependent initiation mechanism, reinitiation of AF episodes was prevented by the inhibition of RyR2 using ryanodine or SR Ca 2+ uptake using thapsigargin. There is paucity of large animal models showing spontaneous AF. In dog, pig, goat, and sheep models, AF is generally initiated by burst pacing, with the duration of inducible AF being quantified as an index of the arrhythmia-maintaining substrate. One notable exception is dogs with chronic left ventricular myocardial infarction, which develop spontaneous AF episodes on sympathetic stimulation with tyramine. 37 AF was because of Ca 2+ -dependent late phase 3 EADs around the left atrium (LA)/pulmonary vein (PV) junction. 37 Spontaneous AF initiation around the LA/PV junction also occurs in aged rats after glycolytic inhibition. 38 In this model, glycolytic inhibition interacts with the fibrotic substrate of the aged atria to amplify Ca 2+ -handling abnormalities that facilitate EAD-mediated triggered activity. 38 Together, these studies support the concept that focal ectopic/triggered firing resulting from Ca 2+ -handling abnormalities, particularly in the atrial myocardium surrounding the PVs, may play an important role in the initiation of AF.
Right atrial (RA) cardiomyocytes from patients with pAF also exhibit an increased incidence of SCaEs and corresponding DADs compared with patients with sinus rhythm. 39 The underlying molecular substrate involves increased SR Ca -dependent triggered activity in cardiomyocytes, AF could also be initiated through processes resulting from direct myofibroblast-cardiomyocyte interactions. 40 In vitro studies show gap junctional coupling through connexin-43 and connexin-45 proteins between cardiomyocytes and myofibroblasts, although big-conductance Ca 2+ -activated K + channels may also play a role. 41, 42 Computational analyses suggest that electrotonic myofibroblast-cardiomyocyte interactions can promote diastolic depolarization of atrial cardiomyocytes because of the relatively depolarized membrane potential of cardiac fibroblasts (≈−30 mV), thereby promoting DADs and ectopic firing. shortening, with spontaneous AF episodes. 45 The molecular mechanisms underlying the initiation of AF were not studied, although APD prolongation with isoprenaline reduces the incidence of AF episodes. 45 Aged spontaneously hypertensive rats have a pronounced fibrotic substrate promoting AF. 46 These rats showed spontaneous atrial tachyarrhythmias associated with an autonomic imbalance with relative vagal hyperactivity, producing repolarization shortening and heterogeneity that preceded the occurrence of arrhythmia. 47 
Role of the PVs
PV sleeves play an important role in the initiation of AF. 48 The isolation of PVs prevents AF recurrence in 75% of patients with pAF. 49 Both structural and functional properties of the PV cardiomyocyte sleeves contribute to their arrhythmogenic potential. 50 The PV sleeves have a tissue architecture consisting of discrete fibers with abrupt changes in fiber direction, resulting in reduced electrotonic load and facilitating the development of focal ectopic activity. The identification of molecular mechanisms promoting ectopic activity around the PVs in humans is difficult because of the limited availability of PV tissue from patients, 51 but recent results showed no differences in gene expression profiles of major ion channel subunits or Ca 2+ -handling proteins between PV sleeves and LA free wall tissue samples from patients with valvular AF. 52 The transcription factor PITX2 is highly expressed around the PVs and is critical for the development of the PV sleeve myocardium. 53 PITX2 downregulates the nodal gene program, suppressing the development of focal ectopic activity around the PVs. Accordingly, reduced PITX2 expression in patients with AF and genetic variants close to the PITX2 gene have been associated with increased AF susceptibility. 54, 55 Animal studies revealed reduced expression of I K1 in PV sleeves, 56 resulting in depolarized resting potentials that facilitate ectopic activity. The propensity for SCaEs was increased in PV regions versus LA or RA appendages in some 57 but not all studies. 58 If human PV sleeve myocytes are vulnerable to SCaEs, this could further explain their importance in AF initiation.
In addition to the re-entry-favoring fiber architecture, effective refractory periods around the PVs are shorter in patients with pAF, 59 further increasing the likelihood of a re-entrant circuit around the PVs that can initiate or maintain AF.
Mechanisms of AF Maintenance
Mechanisms of Cardiac Conduction and Re-entry
Re-entry is promoted by short effective refractory periods and slow impulse conduction. Postrepolarization refractoriness largely results from voltage-dependent inactivation of Na + channels. 60 Atrial Na + channels have been suggested to have a more negative half-inactivation voltage compared with ventricular channels, allowing for greater postrepolarization refractoriness, particularly in the presence of Na + channel blockers. 60 Conduction velocity is mainly determined by excitatory Na + current, cardiomyocyte electric coupling through gap junctions, and muscle bundle architecture. 8, 10, 17 Reduced I Na , decreased gap junctional coupling, and muscle bundle discontinuities resulting from fibrosis all reduce conduction velocity and promote re-entry. Ca 2+ -handling abnormalities can also promote AF maintenance through conduction slowing. 61 Atrial conduction velocity is reduced in mice with a RyR2 catecholaminergic polymorphic ventricular tachycardia mutation causing increased SR Ca 2+ leak and in mouse hearts with acutely elevated intracellular Ca 2+ . 62 The underlying mechanisms seem to involve both acute Ca 2+ -dependent inhibition of Na + channels and chronic downregulation of Nav1.5 expression.
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Experimental Models of Primary Cardiac Conditions Promoting AF Maintenance
APD Changes
In HF because of 3 to 6 weeks of ventricular tachypacing, I Ca,L , I to , and I Ks are reduced; I K1 and T-type Ca 2+ currents are unaltered; and NCX current is increased. 64 Atrial APD is unaltered at slow rates and slightly prolonged at faster rates. 64 Experimental HF also increases the incidence of DADs, likely because of intracellular Ca 2+ overload. 65 In another study of long-term tachypacing-induced HF, an increase in I to , largely unaltered I Ca,L , and reduced I K1 , I Kur , and I Ks were observed, along with a shortening of atrial APD. 66 Together, these studies suggest complex time-dependent HF-induced atrial electric remodeling. 67 Other models have not been characterized as extensively. AF promotion associated with chronic volume overload in sheep is characterized by APD triangulation and I Ca,L reduction. 68 Endurance exercise training increases vagal tone, causing heterogeneous APD shortening via increased sensitivity to acetylcholine because of a reduction in regulators of G-protein signaling proteins. 69 Normal aging is also associated with electric remodeling, including a reduction in I Ca,L and increased I to , although other studies have reported a seemingly contradictory APD prolongation. 68 and aging. 70 These changes are associated with re-entry-promoting conduction abnormalities.
Angiotensin II and TGFβ1 are the major profibrotic signaling molecules, with additional roles for platelet-derived and connective tissue growth factors. 34, 76 HF-induced atrial fibrosis is preceded by increased tissue angiotensin II levels and activation of mitogen-activated protein kinases, c-Jun N-terminal kinase, and extracellular signal-related kinase. 75 Although angiotensin-converting enzyme inhibition prevented these changes, atrial fibrosis was only partially reduced, highlighting the multifactorial nature of atrial fibrosis. 75 The proliferation of fibroblasts and their differentiation into collagen-secreting myofibroblasts play a critical role in fibrosis ( Figure 5) , with atrial fibroblasts showing greater fibrotic responses compared with ventricular fibroblasts. 77 MicroRNA-21 plays a major role in profibrotic remodeling by reducing Sprouty-1. 78 Sprouty-1 is a negative regulator of type 1/2 extracellular signal-related kinase, thereby inhibiting fibroblast survival and density. 78, 79 LA microRNA-21 knockdown suppresses atrial fibrosis and AF substrate development in rats with post-MI HF. 79 MicroRNA-29b suppresses collagen gene expression and is downregulated in canine HF, so microRNA-29 downregulation could contribute to HF-related fibrosis. 80 Fibroblast ion channel remodeling may also promote AF. Ca 2+ permeable transient receptor potential (TRP) canonical-3 (TRPC3) channels regulate cardiac fibroblast proliferation and differentiation, likely by mediating fibroblast Ca 2+ entry that activates extracellular signal-related kinase signaling.
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TRPC3 expression is increased in atria from patients with AF, goats with electrically maintained AF, and dogs with tachypacing-induced HF, because of reduced repression resulting from the downregulation of microRNA-26. 81 In contrast, TRPC3 knockdown decreases canine atrial fibroblast proliferation. 81 Kv1.5 seems to be the principal K + channel α-subunit in fibroblasts, and channel expression is strongly downregulated in HF dogs, thereby promoting fibroblast proliferation and suggesting a functional role in HF-induced AFpromoting fibrosis. 82 Atrial fibroblasts also express Nav1.5 α-subunits and Na + currents when differentiated into myofibroblasts, and the resulting Na + entry may contribute to their arrhythmogenic potential. 83, 84 In addition to promoting muscle bundle discontinuities, myofibroblasts can affect atrial cardiomyocytes through paracrine interactions, notably via angiotensin II and TGFβ1 ( Figure 5 ). 85 Moreover, myofibroblasts promote re-entry via direct electric interaction with cardiomyocytes ( Figure 5 ), 40 by reducing conduction velocity through passive loading and depolarization-induced Na + channel inactivation. Conduction abnormalities are also promoted by impaired cell-to-cell coupling via gap junctions. For example, acute atrial ischemia promotes AF induction by impairing cell-to-cell coupling, causing severe local conduction slowing. 86 HF causes connexin-43 dephosphorylation and associated gap junction lateralization. 73 However, because recovery from HF normalizes atrial function and connexin properties, but not fibrosis, conduction abnormalities, or AF persistence, fibrosis is probably the predominant determinant of AF maintenance in experimental HF. 73 Accordingly, the gap junction stabilizer rotigaptide suppresses AF in acute atrial ischemia but not HF.
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Clinical Disease-Related Atrial Remodeling Promoting AF Maintenance
Patients with valvular heart disease show substantial remodeling of cardiac ion channel gene expression, with additional remodeling because of AF. 88 Left ventricular systolic dysfunction is associated with APD shortening in the presence of unaltered I Ca,L , I K1 , or sustained outward current, possibly because of increased I to . 89 In contrast, mitral valve disease and low left ventricular ejection fraction are associated with reduced I Ca,L , 90 whereas atrial dilatation involves reduced I Ca,L and I to . 91 It is likely that such disease-related remodeling predisposes to AF, especially in combination with AF risk factors. In addition, AF can also be mediated by atrial stretch resulting from hypertension, HF, or mitral valve disease. Atrial stretch is a common paradigm in AF-related conditions and might importantly contribute to AF-promoting structural remodeling. 92 The consequences of atrial pressure and volume overload could also be directly related to these underlying diseases, independent of atrial ion channel remodeling.
AF-Induced Remodeling Promoting AF Maintenance in Animal Models
In addition to disease-related remodeling, AF-induced atrial remodeling seems to play a major role in the maintenance, progression, and stabilization of AF. 34, [93] [94] [95] 
APD Shortening
Atrial tachycardia pacing causes a pronounced reduction in atrial APD associated with reduced I Ca,L and I to caused by the downregulation of the underlying Cav1.2 and Kv4.3 subunit expression, an increase in constitutively active I K,ACh , 96 whereas I K1 , rapid delayed-rectifier K + current, I Ks , I Kur , and T-type Ca 2+ currents were unaltered. 97, 98 Rapid atrial cardiomyocyte firing increases intracellular Ca 2+ , activating the Ca 2+ -dependent phosphatase calcineurin. 99 Calcineurin dephosphorylates the nuclear factor of activated T cells, promoting its translocation to the nucleus, where it represses transcription of Cav1.2 ( Figure 6 ). 99 MicroRNA-328 upregulation and repression of Cav1.2 may also be involved in this process, 100 and I Ca,L downregulation can also be because of Ca 2+ -dependent activation of calpain, causing proteolitic breakdown of L-type Ca 2+ -channels. 101 Overall, reduced I Ca,L prevents pacing-induced Ca 2+ overload at the expense of reentry-promoting APD shortening.
The Ca 2+ /calcineurin/nuclear factor of activated T cells-dependent pathway can reduce I to in ventricular cardiomyocytes, suggesting that the rate-dependent reduction 
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April 25, 2014 in I to in AF could also be mediated via this pathway. 102, 103 Interestingly, similar mechanisms are responsible for the ratedependent upregulation of I K1 : nuclear factor of activated T cells reduces the expression of the inhibitory microRNA-26, removing translational inhibition of Kir2.1 by microRNA-26 ( Figure 6 ). 104 The rate-dependent increase in constitutively active I K,ACh is also Ca 2+ -dependent and is at least partly mediated via calpain, which breaks down classical protein kinase C type α-isoforms (Figure 6 ). 105 Several studies have suggested a role for small-conductance Ca 2+ -activated K + (SK) currents in AF. The expression of the SK1 subunit and SK channel open probability are enhanced in dogs with atrial tachycardia remodeling, promoting repolarization shortening, 106 whereas the inhibition of SK channels prolongs atrial repolarization and reduces AF duration in several animal models.
106,107
Ca 2+ -Handling Abnormalities Ca 2+ transient amplitude is reduced in dogs with atrial tachycardia remodeling, contributing to atrial contractile dysfunction. 108, 109 The reduced Ca 2+ transient amplitude feeds back on repolarization, contributing to reduced APD rate dependence in AF. 110, 111 In addition, atrial tachycardia remodeling induces impaired Ca 2+ wave propagation to the cell center and is associated with hypophosphorylation-dependent myofilament desensitization because of reduced expression of PKA and increased activity of PP1 and CaMKII. 110 In contrast, PKA-dependent phosphorylation of RyR2 is increased in dogs with atrial tachypacing, similar to patients with chronic AF (cAF), and is associated with decreased RyR2-FKBP12.6 interaction. 112 In goats with persistent AF, PKA-dependent phospholamban phosphorylation is reduced (decreasing SR Ca 2+ uptake), whereas CaMKII-dependent RyR2 phosphorylation is increased (increasing SR Ca 2+ leak), reducing SR Ca 2+ load and contributing to reduced contractility associated with AF. 113 In sheep with persistent AF, the coupling efficiency between RyR and L-type Ca 2+ channels is decreased, contributing to reduced SR Ca 2+ release and Ca 2+ transient amplitude despite normal SR Ca 2+ load.
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Conduction Abnormalities and Structural Remodeling
Long-term atrial pacing leads to conduction slowing in several animal models. In canine atrial tachycardia remodeling, reduced conduction velocity is at least partly because of I Na downregulation. 115 Heterogeneously reduced gap junction coupling because of connexin remodeling can also contribute to atrial conduction slowing. Heterogeneity in connexin-40 distribution correlated with increased AF stability in atrial cardiomyocytes from goats with AF because of repetitive burst pacing. 116 Similarly, connexin-40 expression in the PVs is decreased in the canine tachypacing model, possibly because of increased degradation by calpains activated by the Ca 2+ -loading effects of high atrial rates. 117 Although less pronounced than in HF, atrial tachycardia remodeling promotes atrial contractile dysfunction and causes atrial dilatation. 93 Calpain activation contributes to troponin breakdown and subsequent contractile dysfunction after high-frequency activation. 118 Atrial dilatation promotes atrial remodeling and fibrosis through increased atrial stretch. 92 Atrial tachycardia also results in atrial fibrosis and increased susceptibility to AF, even in the absence of ventricular dysfunction, indicating that a high atrial rate per se can cause fibrosis. 119 Recent work has identified components of the underlying signaling pathways. Serum from tachypaced atrial myocytes promotes fibroblast differentiation to collagen-secreting myofibroblasts, through autocrine and paracrine mechanisms. 120 Rapid atrial activation in rabbits produces fibrosis associated with increased angiotensin II and TGFβ1, activation of the Smad2/3 pathway, and inhibition of the TGFβ1/Smad-mediated fibrosis antagonist Smad7, effects that are prevented by angiotensin II type 1 receptor blockade. 121 Tachycardia-induced nuclear factor of activated T cell-mediated decreases in fibroblast microRNA-26 may also contribute to structural remodeling. Because microRNA-26 represses TRPC3 gene expression, microRNA-26 reductions enhance TRPC3 expression, promoting fibroblast proliferation/myofibroblast differentiation.
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AF-Maintaining Substrates Resulting from AF-Induced Remodeling in Patients
A comparison of the electrophysiological and molecular characteristics of atrial cardiomyocytes from pAF versus patients with long-standing persistent cAF provides strong indications about the AF-promoting consequences of atrial tachycardia remodeling, because patients with pAF had been in normal sinus rhythm for days to weeks at the time of cardiac surgery, whereas patients with cAF had a persistent high atrial rate before and during surgery.
APD Shortening
In contrast to patients with pAF, atrial myocytes from patients with cAF show decreased APD. Depolarizing I Ca,L is consistently reduced in cAF, [122] [123] [124] likely because of an adaptive mechanism to protect atrial myocytes from toxic Ca 2+ overload resulting from fast rates. Reduced I Ca,L contributes both to reduced APD, promoting re-entry, and decreased Ca 2+ transient amplitude, reducing atrial contractility. Cav1.2 α 1C -subunit expression is reduced in cAF atrial cardiomyocytes in most but not all studies, 125 possibly because of an increase in microRNA-328. 100 In addition, there is evidence for altered Cav1.2 phosphorylation, 124,126 S-nitrosylation, 127 and channel subunit breakdown by calpain. 128 The complex molecular basis of reduced I Ca,L in cAF suggests that the precise mechanisms may differ among patients.
Increased inward-rectifier K + currents also contribute to APD shortening in cAF. LA I K1 is increased in both pAF and cAF. 129 The increase in I K1 is because of increased protein expression of underlying Kir2.1 subunits, 129, 130 probably through a reduction of microRNAs that normally repress Kir2.1 translation 104, 131 and an enhancement of single-channel open probability. 132 The increased single-channel open probability may involve stronger channel dephosphorylation by PP1 and serine/threonine protein phosphatase type 2A in cAF. 133 Agonist-activated I K,ACh is larger in RA than in LA from patients with sinus rhythm, but is decreased in RA of pAF and cAF because of a reduction in underlying Kir3. 135 This Na + -dependent regulation is lost in cAF, possibly because of a more pronounced reduction of the Na + -sensitive subunit Kir3.4 than Kir3.1, and further reduces I K,ACh at fast rates with increased intracellular [Na + ]. 135 I K,ACh also develops agonist-independent (constitutive) activity in cAF. 132 The constitutive activity of I K,ACh in cAF is promoted by abnormal channel phosphorylation by novel protein kinase C isoforms. 133 Computational studies show that increased total inward-rectifier K + current in cAF is the major contributor to the stabilization of re-entrant rotors by shortening APD and hyperpolarizing the resting membrane potential. 136 There is evidence for increased I Ks in patients with cAF, which might contribute to APD shortening. 137, 138 The molecular mechanisms underlying increased I Ks are unknown. Increased, decreased, and unaltered mRNA levels of the underlying KCNQ1 α-subunit have been reported in patients with cAF. 88, 125 The expression of the KCNE1 β-subunit is reduced in patients with valvular heart disease, without differences between sinus rhythm and patients with cAF. 88 In one study, SK current was increased in cAF atrial cardiomyocytes and augmented by high-frequency depolarizing pulses. 139 The increase in SK current was prevented by the inhibition of retrograde channel trafficking, suggesting a rate-dependent influence on membrane channel availability. 139 However, another study reported reduced SK channel expression in cAF atrial cardiomyocytes, 140 possibly because of increased microRNA-499, downregulating the SK3 subunit. 141 Despite reduced APD at full repolarization, APD at 20% repolarization is generally prolonged. 142 This effect is partly because of smaller I to 123 through reduced expression of the underlying Kv4.3 subunit. I to reduction is more pronounced in LA than in RA. 137 Similarly, I Kur and Kv1.5 subunits are reduced in cAF. 137, 143, 144 I Kur reduction has indirect effects on other currents, and the overall impact on APD depends on AP morphology. 142 For example, there is evidence that reduced I Kur can promote EADs in the presence of sympathetic stimulation. 145, 146 Ca 2+ -Handling Abnormalities Although SCaEs and DADs are more prevalent in both pAF and cAF myocytes compared with sinus rhythm, the underlying molecular mechanisms are distinct (Figure 7 ). Several groups have highlighted a critical role for CaMKII-dependent RyR2 phosphorylation in SR Ca 2+ leak and SCaEs in cAF.
147-149
The oxidation of methionine 281/282 is increased in patients with cAF and contributes to increased CaMKII activity, making CaMKII a critical molecular signal coupling AF-related oxidative stress to proarrhythmic Ca
2+
-handling abnormalities. 150 PKA-dependent RyR2 hyperphosphorylation has also been observed in patients with cAF 112, 149 and might promote RyR2 dysfunction by promoting dissociation of the stabilizing FKBP12.6 subunit from the RyR2 channel, 112 although this is not unanimously accepted. 151, 152 In addition, the expression - 149 or reduced expression of the SERCA2a inhibitor sarcolipin. 153, 154 The increase in PP1 and protein phosphatase type 2A activity in patients with cAF would be expected to reduce phosphorylation levels 155 ; however, cAMP levels are increased in cAF, 149 possibly because of reduced cAMP-hydrolyzing phosphodiesterase type 4, 156 promoting PKA activation. In addition, increased PKA-dependent activation of the PP1 inhibitory protein inhibitor-1, which controls PP1 in the SR compartment, 157 could explain phospholamban hyperphosphorylation because of local reductions in PP1 activity. 155 
Conduction Abnormalities and Structural Remodeling
Earlier studies showed no change in I Na or mRNA expression of the Nav1.5 α-subunit in patients with cAF. 158, 159 However, recent studies reported reduced peak I Na in patients with AF that could contribute to re-entry-promoting conduction slowing. 160, 161 In addition, persistent/late I Na is increased in some studies. 160 Although the exact functional consequences are presently unknown, patients with early-onset lone AF also exhibit a high prevalence of Na + channel mutations that increase persistent/late I Na . 162 Connexin-40/connexin-43 mRNA and protein expression are altered in patients with AF, potentially contributing to re-entry-promoting conduction abnormalities. 163 Reduced connexin-40 expression has been reported in some studies, 88, 164 whereas others reported increased expression at the transverse cell membrane, promoting heterogeneous conduction, which was reduced by β-adrenoceptor blockade. 165 Fibrosis is common in patients with AF, 166 and connexin-43 remodeling correlates with atrial fibrosis in patients, 167 suggesting an interaction between these re-entry-promoting factors. High-density electroanatomic mapping in patients identified conduction abnormalities that correlated with AF progression. Because conduction abnormalities also correlated with low electrogram voltage and percentage of complex electrograms, it was suggested that conduction slowing was because of AF-related fibrosis. 168 There is evidence that fibroblast remodeling can occur as a consequence of AF, thereby promoting AF progression and stabilization. Beside the increase in TRPC3, TRP melastatin-related 7 channels are upregulated in patients with cAF and form a major Ca 2+ permeation pathway in human atrial fibroblasts. 169 The downregulation of TRP melastatin-related 7 reduced AF fibroblast differentiation, and the atrial profibrotic effects of TGFβ1 require TRP melastatin-related 7-mediated Ca 2+ signals. 169 Recent work suggests that fibrocytes (bone marrow-derived fibroblast-like cells) may also be involved in atrial fibrosis of patients with cAF because they display stronger proliferative capacity and higher expression of collagen-I and α-smooth muscle actin.
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Mechanisms of AF Progression
As depicted in Figure 1 , the progression of AF substrate occurs as a result of both AF-related remodeling and remodeling because of age and heart disease. The mechanistic components of the underlying processes are discussed in detail above. The key components include changes in ion currents that promote re-entry by abbreviating APD/refractory period, alterations in connexin expression, Na + current decreases and fibrotic remodeling that cause conduction slowing, and changes in Ca 2+ handling that induce focal ectopic impulse formation. AF progression can also be because of the evolution of atrial changes caused by underlying cardiac and noncardiac diseases, independent of any AF-induced remodeling. For example, AF is an established risk factor for worsening HF, 171, 172 and the evolution of mixed-type atrial remodeling in patients with HF can create a vicious cycle further accelerating AF progression. In contrast, some patients show limited AF progression, remaining in paroxysmal AF for decades. The mechanisms explaining this heterogeneity in the natural history of AF are at present largely unknown.
Gaps in Current Knowledge and Translational Prospects
Despite the enormous advances in our understanding of the molecular pathophysiology of AF during the past decades, there are still numerous important gaps that need to be addressed. Structural remodeling seems a key for AF stabilization and therapy resistance. For many years, researchers focused on quantifying fibrosis as an index of structural remodeling severity. However, processes such as fat accumulation, 173 edema, amyloidosis, 174 and other still unidentified factors might have great importance for AF progression and stabilization. The dynamic nature and specific pattern of myofibroblast-cardiomyocyte interactions is just emerging, and the extent to which they contribute to the initiation and maintenance of AF is unclear.
The upstream and downstream signaling pathways leading to focal ectopic/triggered firing and AF-maintaining re-entry need precise delineation. The identification of nodal points in atrial cardiomyocyte signaling will be a key to sort out common determinants among pathophysiological contributors. This may help to identify and target key drivers of the fibrillatory process.
Cardiac genomics and proteomics require further exploration and clarification. Advanced bioinformatics and computational modeling approaches have the capacity to integrate and synthesize current insights to grapple with the complexity of AF. Computational science might play a key translational role in understanding and combating the mechanisms of AF in vivo, because sophisticated multiscale computational modeling can integrate the cellular and molecular processes in the second and third dimensions, providing key insights into the impact of molecular events for AF at the multicellular tissue level.
Although animal models have provided a wealth of information on AF pathophysiology, they have important limitations. 46 Few currently available experimental models show spontaneous AF occurrence and progression as observed in patients. Therapeutic interventions that are effective in animal models are often unsuccessful in patients, and the interpretation of genetic models may be hindered by complex compensatory phenomena. 18, 46 Animal models tend to focus on specific isolated pathophysiological stressors applied for a relatively short period of time in the absence of other forms of disease (eg, AF because of experimental hypertension, HF, ischemia, diabetes mellitus, thyroid dysfunction). Clinical AF is often the result of many years of complex pathophysiology including multiple disease conditions, modified by extraneous drug therapy. Thus, the mechanisms observed in much simpler experimental models might operate in complex combinations, or even not at all, in patients with similar clinical conditions. Newer methods involving in vivo imaging of structural and functional substrate in patients may hold the key to therapeutic application of fundamental concepts, [175] [176] [177] [178] but currently available invasive and noninvasive mapping methods that assess the dynamics of AF in patients do not adequately exploit our knowledge of the cellular and molecular pathophysiology of AF.
Importantly, the causes of AF are extremely diverse. Rather than a specific disease, AF is a final end product of a wide range of clinical conditions, as discussed in detail in another article of this compendium. 15 The exact combination of individual pathophysiological processes contributing to AF is likely distinct in specific patient subsets. 15 Improved understanding of the connection between causes of AF and cellular mechanisms is required to provide tailored therapies for select patient cohorts.
